GILD

#83
Gilead Sciences, Inc. - Common Stock
148.8 6 USD
+0.01%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
148.85
148.86
Year Range
108.46
157.27
Daily Change
+0.52%
Monthly Change
+10.75%
6 month change
+0.72%
Year Change
+32.19%
Previous Close
148.0 9
Open
148.8 5
Low
148.8 5
High
148.8 6
Volume
280
Open full chart

Financials

Overview Statement Statistics Dividends Documents

2026

Current report, Q3 FY2026
GILEAD SCIENCES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
GILEAD SCIENCES, INC. quarterly report, Q2 FY2026
10-Q
Institutional holdings, Q2 FY2026
GILEAD SCIENCES, INC. institutional holdings, Q2 FY2026
13F-HR
INFORMATION TABLE, Q2 FY2026
GILEAD SCIENCES, INC. INFORMATION TABLE, Q2 FY2026
INFORMATION TABLE
Current report, Q2 FY2026
GILEAD SCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GILEAD SCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GILEAD SCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GILEAD SCIENCES, INC. current report, Q2 FY2026
8-K
Institutional holdings, Q1 FY2026
GILEAD SCIENCES, INC. institutional holdings, Q1 FY2026
13F-HR
Quarterly report, Q1 FY2026
GILEAD SCIENCES, INC. quarterly report, Q1 FY2026
10-Q

GILEAD SCIENCES, INC. current report, Q3 FY2025

Full document

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2025
Reporting Period: Quarter ended June 30, 2025

This filing announces the issuance of a press release detailing financial results for the second quarter of 2025. The report includes both GAAP and non-GAAP financial measures, with reconciliations provided in the attached press release (Exhibit 99.1).

Key Financial Metrics

The provided text serves as a cover document for the financial results and does not contain specific numerical values for the following metrics:

  • Revenue
  • Net Profit or Loss
  • Cash Flow
  • Profit Margins
  • Debt Levels
  • Liquidity Position

Investors must refer to Exhibit 99.1 (the Press Release) for detailed financial data.

Material Changes

The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. It only confirms that results for the quarter ended June 30, 2025, have been announced.

Guidance, Outlook, and Risks

Management Commentary: Management utilizes non-GAAP measures for internal operating, budgeting, and financial planning purposes. The filing notes that non-GAAP measures may be defined differently by other companies and should supplement, not replace, GAAP results.

Legal Disclaimer: The information in Item 2.02 and Item 9.01, including the press release, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be incorporated by reference into other filings.

Guidance and Risks: The text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclaimer regarding the non-GAAP measures.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for actual revenue, earnings, and cash flow figures.
  • Examine the reconciliation tables (pages 10-12 of the press release) to understand adjustments between GAAP and non-GAAP results.
  • Verify the specific drivers of performance for the quarter ended June 30, 2025, as they are not detailed in this 8-K summary.
  • Confirm whether any forward-looking guidance was issued in the press release, as it is not present in this filing text.

News